Vargason AM, Anselmo AC, Mitragotri S. The evolution of commercial drug delivery technologies. Nat Biomed Eng. 2021;5(9):951–67. https://doi.org/10.1038/s41551-021-00698-w.

Article  PubMed  Google Scholar 

Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965;13(1):238–52. https://doi.org/10.1016/s0022-2836(65)80093-6.

Article  CAS  PubMed  Google Scholar 

https://pmc.ncbi.nlm.nih.gov/. Accessed January 16, 2025

https://www.britannica.com/science/nanomedicine

Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941–51. https://doi.org/10.1038/nbt.3330.

Article  CAS  PubMed  PubMed Central  Google Scholar 

https://www.cancer.gov/nano/research/nclhttps://www.euncl.org/

https://www.lne.fr/fr/evenements/workshop-nanomedicine

Halwani AA. Development of pharmaceutical nanomedicines: from the bench to the market. Pharmaceutics. 2022;14(1):106. https://doi.org/10.3390/pharmaceutics14010106.

Article  CAS  PubMed  PubMed Central  Google Scholar 

https://www.precedenceresearch.com/nanomedicine-market. Accessed January 16, 2025

https://www.statista.com/outlook/hmo/pharmaceuticals/vaccines/covid-19-vaccines/worldwide. Accessed January 16, 2025

Lankheet S, Kampkuiper N, Nellensteijn J, Hekman E, Tuijthof G, Schröder F, Koenrades M. Sacroiliac joint fusion guided by intraoperatively superimposed virtual surgical planning using simulated fluoroscopic images. Brain Spine. 2024;4:102905. https://doi.org/10.1016/j.bas.2024.102905.

Article  PubMed  PubMed Central  Google Scholar 

Metselaar JM, Lammers T. Challenges in nanomedicine clinical translation. Drug Deliv Transl Res. 2020;10(3):721–5. https://doi.org/10.1007/s13346-020-00740-5.

Article  PubMed  PubMed Central  Google Scholar 

Soga O, van Nostrum CF, Hennink WE. Poly(N-(2-hydroxypropyl) methacrylamide Mono/di lactate): a new class of biodegradable polymers with tuneable thermosensitivity. Biomacromolecules. 2004 May-Jun;5(3):818–21. https://doi.org/10.1021/bm049955q.

Rijcken CJ, Snel CJ, Schiffelers RM, van Nostrum CF, Hennink WE. Hydrolysable core-crosslinked thermosensitive polymeric micelles: synthesis, characterisation and in vivo studies. Biomaterials. 2007;28(36):5581–93. https://doi.org/10.1016/j.biomaterials.2007.08.047.

Crielaard BJ, Rijcken CJ, Quan L, van der Wal S, Altintas I, van der Pot M, Kruijtzer JA, Liskamp RM, Schiffelers RM, van Nostrum CF, Hennink WE, Wang D, Lammers T, Storm G. Glucocorticoid-loaded core-cross-linked polymeric micelles with tailorable release kinetics for targeted therapy of rheumatoid arthritis. Angew Chem Int Ed Engl. 2012;51(29):7254–8. https://doi.org/10.1002/anie.201202713.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Talelli M, Barz M, Rijcken CJ, Kiessling F, Hennink WE, Lammers T. Core-Crosslinked polymeric micelles: principles, preparation, biomedical applications and clinical translation. Nano Today. 2015;10(1):93–117. https://doi.org/10.1016/j.nantod.2015.01.005.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu Q, Rijcken CJ, Bansal R, Hennink WE, Storm G, Prakash J. Complete regression of breast tumour with a single dose of docetaxel-entrapped core-cross-linked polymeric micelles. Biomaterials. 2015;53:370–8. https://doi.org/10.1016/j.biomaterials.2015.02.085.

Article  CAS  PubMed  Google Scholar 

Rijcken CJF, De Lorenzi F, Biancacci I, Hanssen RGJM, Thewissen M, Hu Q, Atrafi F, Liskamp RMJ, Mathijssen RHJ, Miedema IHC, Menke-van der Houven van Oordt CW, van Dongen GAMS, Vugts DJ, Timmers M, Hennink WE, Lammers T. Design, development and clinical translation of CriPec®-based core-crosslinked polymeric micelles. Adv Drug Deliv Rev. 2022;191:114613. https://doi.org/10.1016/j.addr.2022.114613

Atrafi F, Dumez H, Mathijssen RHJ, van der Menke CW, Rijcken CJF, Hanssen R, Eskens FALM, Schöffski P. A phase I dose-escalation and Pharmacokinetic study of a micellar nanoparticle with entrapped docetaxel (CPC634) in patients with advanced solid tumours. J Control Release. 2020;325:191–7. https://doi.org/10.1016/j.jconrel.2020.06.020.

Article  CAS  PubMed  Google Scholar 

Miedema IHC, Zwezerijnen GJC, Huisman MC, Doeleman E, Mathijssen RHJ, Lammers T, Hu Q, van Dongen GAMS, Rijcken CJF, Vugts DJ. Menke-van der Houven Van oordt CW. PET-CT imaging of polymeric nanoparticle tumor accumulation in patients. Adv Mater. 2022;34(21):e2201043. https://doi.org/10.1002/adma.202201043.

Article  CAS  PubMed  Google Scholar 

Gonda K, Negishi H, Takano-Kasuya M, Kitamura N, Furusawa N, Nakano Y, Hamada Y, Tokunaga M, Higuchi H, Tada H, Ishida T. Heterogeneous drug efficacy of an Antibody-Drug conjugate visualized using simultaneous imaging of its delivery and intracellular damage in living tumor tissues. Transl Oncol. 2020;13(6):100764. https://doi.org/10.1016/j.tranon.2020.100764.

Article  PubMed  PubMed Central  Google Scholar 

van Dongen GAMS. Improving tumor penetration of antibodies and Antibody-Drug conjugates: taking away the barriers for Trojan horses. Cancer Res. 2021;81(15):3956–7. https://doi.org/10.1158/0008-5472.

Article  PubMed  Google Scholar 

Marusyk A, Janiszewska M, Polyak K. Intratumor heterogeneity: the Rosetta stone of therapy resistance. Cancer Cell. 2020;37(4):471–84. https://doi.org/10.1016/j.ccell.2020.03.007.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Duncan KD, Pětrošová H, Lum JJ, Goodlett DR. Mass spectrometry imaging methods for visualizing tumor heterogeneity. Curr Opin Biotechnol. 2024;86:103068. https://doi.org/10.1016/j.copbio.2024.103068.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Atrafi F, van Eerden RAG, van Hylckama Vlieg MAM, Oomen-de Hoop E, de Bruijn P, Lolkema MP, Moelker A, Rijcken CJ, Hanssen R, Sparreboom A, Eskens FALM, Mathijssen RHJ, Koolen SLW. Intratumoral comparison of nanoparticle entrapped docetaxel (CPC634) with conventional docetaxel in patients with solid tumors. Clin Cancer Res. 2020;26(14):3537–45. https://doi.org/10.1158/1078-0432.CCR-20-0008.

Article  CAS  PubMed  Google Scholar 

Atrafi F, van Eerden RAG, Koolen SLW, de Bruijn P, Rijcken CJF, Hanssen R, Eskens FALM, Lolkema MP, Oomen-de Hoop E, Damman J, Mathijssen RHJ. Docetaxel skin exposure and micronucleation contributes to skin toxicity caused by CPC634. Cancers (Basel). 2021;13(15):3741. https://doi.org/10.3390/cancers13153741.

Article  CAS  PubMed  Google Scholar 

Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs. 1995;6(3):339–55. https://doi.org/10.1097/00001813-199506000-00001.

Article  CAS  PubMed  Google Scholar 

Rosing H, Lustig V, van Warmerdam LJ, Huizing MT, ten Bokkel Huinink WW, Schellens JH, Rodenhuis S, Bult A, Beijnen JH. Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion. Cancer Chemother Pharmacol. 2000;45(3):213–8. https://doi.org/10.1007/s002800050032.

Article  CAS  PubMed  Google Scholar 

Boere I, Vergote I, Hanssen R, Jalving M, Gennigens C, Ottevanger P, van de Wouw YJ, Rijcken CJF, Mathijssen RHJ, Ledermann J. CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer. Int J Gynecol Cancer. 2023;33(8):1247–52. https://doi.org/10.1136/ijgc-2023-004308.

Article  PubMed  Google Scholar 

Von Hoff DD, Mita MM, Ramanathan RK, Weiss GJ, Mita AC, LoRusso PM, Burris HA 3rd, Hart LL, Low SC, Parsons DM, Zale SE, Summa JM, Youssoufian H, Sachdev JC. Phase I study of PSMA-Targeted Docetaxel-Containing nanoparticle BIND-014 in patients with advanced solid tumors. Clin Cancer Res. 2016;22(13):3157–63. https://doi.org/10.1158/1078-0432.CCR-15-2548.

Article  CAS  Google Scholar 

https://starpharma.com/news/view/750/positive-dep-docetaxel-phase-2-results-asx-announcement

van der Veldt AA, Hendrikse NH, Smit EF, Mooijer MP, Rijnders AY, Gerritsen WR, van der Hoeven JJ, Windhorst AD, Lammertsma AA, Lubberink M. Biodistribution and radiation dosimetry of 11 C-labelled docetaxel in cancer patients. Eur J Nucl Med Mol Imaging. 2010;37(10):1950–8. https://doi.org/10.1007/s00259-010-1489-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

https://www.linkedin.com/posts/simonbl_probabilityofsuccess-ptrs-pos-activity-7274695863514390528-JESq

https://www.norstella.com/why-clinical-development-success-rates-falling

Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity. 2023;56(10):2188–205. https://doi.org/10.1016/j.immuni.2023.09.011.

Article  CAS  PubMed